Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Dideoxycytidine: current clinical experience and future prospects. A summary.

S Broder1, R Yarchoan

  • 1National Cancer Institute, National Institutes of Health, Bethesda, Maryland 20892.

The American Journal of Medicine
|May 21, 1990
PubMed
Summary

Lower doses of 2

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

No evidence of ongoing HIV replication or compartmentalization in tissues during combination antiretroviral therapy: Implications for HIV eradication.

Science advances·2019
Same author

A20/TNFAIP3 inhibits NF-κB activation induced by the Kaposi's sarcoma-associated herpesvirus vFLIP oncoprotein.

Oncogene·2012
Same author

Imaging techniques for Kaposi's sarcoma.

Journal of HIV therapy·2008
Same author

Measurement of in vitro specific-antibody synthesis.

Current protocols in immunology·2008
Same author

Quantitative assessment of tumor vasculature and response to therapy in kaposi's sarcoma using functional noninvasive imaging.

Technology in cancer research & treatment·2004
Same author

Microbial disease in humans: A genomic perspective.

Molecular diagnosis : a journal devoted to the understanding of human disease through the clinical application of molecular biology·2002

Area of Science:

  • Virology
  • Immunology
  • Pharmacology

Background:

  • 2',3'-dideoxycytidine (ddC) shows promise in treating AIDS patients, but peripheral neuropathy is a significant dose-limiting toxicity.
  • Lower ddC doses may preserve antiviral efficacy while mitigating neurotoxicity.
  • Combination therapies are being explored to improve treatment outcomes and reduce adverse effects.

Purpose of the Study:

  • To investigate the potential of reduced-dose 2',3'-dideoxycytidine (ddC) regimens for treating AIDS.
  • To evaluate the safety and efficacy of simultaneous or alternating administration of ddC with zidovudine.
  • To explore strategies for minimizing ddC-associated toxicities while maintaining antiviral activity.

Main Methods:

  • Clinical trials are examining combined and alternating schedules of ddC and zidovudine.
  • Dose reduction strategies are being assessed to manage peripheral neuropathy.
  • In vitro studies evaluate the susceptibility of zidovudine-resistant strains to ddC.

Main Results:

  • Lower doses of ddC may retain antiviral activity and reduce the incidence of peripheral neuropathy.
  • Combination therapy with zidovudine may offer synergistic benefits and reduced toxicity.
  • ddC demonstrates efficacy against zidovudine-resistant HIV strains in vitro.

Conclusions:

  • Optimized dosing and combination strategies involving ddC hold potential for improved AIDS management.
  • Further research is needed to establish the optimal use of ddC in clinical settings.
  • ddC remains an experimental drug, requiring use within approved clinical protocols.

Related Experiment Videos